NCI Director Speaks about Cancer Care in the Time of COVID

NCI at ASCO 2020 Saturday, May 30 Join NCI Director, Dr. Norman E. Sharpless, as he participates in a panel presentation on COVID-19 and cancer research. In addition, NCI experts will participate in sessions during the ASCO virtual conference. Be sure to check out the full list of conference abstracts for details and additional sessions.

TODAY: Dr. Sharpless Presents: Cancer Care in the Time of COVID NCI Director Dr. Sharpless will discuss the impact of COVID-19 on cancer care and research, including the decrease in the accrual to clinical trials. He will also address how NCI plans to move forward to ensure cancer research progress, how the cancer community has already stepped up, and ways that NCI has responded to COVID-19 including modifications to the clinical trial processes, a Tocilizumab compassionate use study, and a national COVID-19 natural history study. Tune in Today at 4:30 p.m. (ET) Join Us to Learn More About NCCAPS NCI recently launched a national, longitudinal study of COVID-19 in people with cancer. The NCI COVID-19 in Cancer Patients Study (NCCAPS) will help scientists answer key questions about COVID-19’s impact on cancer patients, as well as cancer’s impact on the course of COVID-19.  We invite you to join us in June for an informational presentation. Click here to be notified of this future session. Sessions Featuring NCI Experts NCI’s cancer research experts are participating in poster sessions and presentations throughout the meeting. Watch them on-demand and be sure to check out the ASCO Meeting Library for details. Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers. NCI Participants: Christian Hinrichs, Scott Norberg, Nisha Nagarsheth, Andrew Sinkoe, Thomas Meyer, Jennifer Ann Kanakry, Nikolaos Gkitsas Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. NCI Participant: Larissa Korde Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F NCI Participants: Lisa McShane, Larry V Rubinstein, Mickey Williams, Lyndsay Harris, Alice P. Chen, Keith Flaherty, David R Patton Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma. NCI Participants: W Marston Linehan, Ramaprasad Srinivasan Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. NCI Participants: Ramaprasad Srinivasan, Sandeep Gurram, Munjid Al Harthy, Abhinav Sidana, Mark Wayne Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy Vocke, Peter L Choyke, Lori Long, Joanna Shih, Maria J Merino, W. Marston Linehan A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. NCI Participant: Elise C Kohn Underdiagnosis and undertreatment of modifiable cardiovascular risk factors: A Childhood Cancer Survivor Study (CCSS) report. NCI Participant: Todd M Gibson Neuroleptic rotation for refractory agitation in cancer patients with delirium in the acute palliative care unit: A double-blind randomized clinical trial. NCI Participant: Terri Armstrong Connect with NCI Visit our NCI at ASCO page for resources, funding opportunities, and more information on NCI's presence at ASCO's Virtual Scientific Program, or find us in the ASCO2020 Virtual Exhibit Hall! To join the discussion, follow NCI on Twitter at @theNCI and Instagram at @nationalcancerinstitute.